CY1121386T1 - Μεθοδος για την προβλεψη αποκρισης των ασθενειων σε φαρμακολογικη θεραπευτικη αγωγη σαπερονης - Google Patents

Μεθοδος για την προβλεψη αποκρισης των ασθενειων σε φαρμακολογικη θεραπευτικη αγωγη σαπερονης

Info

Publication number
CY1121386T1
CY1121386T1 CY20191100100T CY191100100T CY1121386T1 CY 1121386 T1 CY1121386 T1 CY 1121386T1 CY 20191100100 T CY20191100100 T CY 20191100100T CY 191100100 T CY191100100 T CY 191100100T CY 1121386 T1 CY1121386 T1 CY 1121386T1
Authority
CY
Cyprus
Prior art keywords
saperone
gal
preventing disease
pharmacological treatment
disease response
Prior art date
Application number
CY20191100100T
Other languages
English (en)
Inventor
Elfrida Benjamin
Hung V. Do
Xiaoyang Wu
John Flanagan
Brandon Wustman
Original Assignee
Amicus Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40957500&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1121386(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amicus Therapeutics, Inc. filed Critical Amicus Therapeutics, Inc.
Publication of CY1121386T1 publication Critical patent/CY1121386T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
    • G01N2333/94—Hydrolases (3) acting on glycosyl compounds (3.2) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/38—Pediatrics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

Μια μέθοδος σύνταξης ενός πίνακα αναφοράς θεραπευτικής αντιμετώπισης, ο οποίος υποδεικνύει την αποκρισιμότητα μιας ή περισσοτέρων ειδικών μεταλλάξεων ενός α-Gal Α σε μια ειδική φαρμακολογική σαπερόνη, με την μέθοδο να περιλαμβάνει: την ανάλυση in vitro της απόκρισης στην ειδική φαρμακολογική σαπερόνη εντός ενός κυττάρου ξενιστή, το οποίο έχει μετασχηματισθεί με έναν φορέα νουκλεϊνικού οξέος, ο οποίος κωδικοποιεί έναν πρώτο μεταλλάκτη α-Gal Α και τη σύνταξη ενός καταλόγου, υπό μορφή πίνακα, αποκρίσιμων και μη-αποκρίσιμων μεταλλαγμένων μορφών ενός α-Gal Α. Η ειδική φαρμακολογική σαπερόνη είναι 1-δεοξυγαλακτονοζιριμυκίνη ή ένα φαρμακευτικό άλας ή εστέρας και το πρώτο κύτταρο είναι ένα ΗΕΚ-293 MSR κύτταρο.
CY20191100100T 2008-02-12 2019-01-24 Μεθοδος για την προβλεψη αποκρισης των ασθενειων σε φαρμακολογικη θεραπευτικη αγωγη σαπερονης CY1121386T1 (el)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US2814108P 2008-02-12 2008-02-12
US3568408P 2008-03-11 2008-03-11
US9363108P 2008-09-02 2008-09-02
US11349608P 2008-11-11 2008-11-11
EP09710178.6A EP2252313B1 (en) 2008-02-12 2009-02-12 Method to predict response to pharmacological chaperone treatment of diseases
PCT/US2009/033963 WO2009102895A2 (en) 2008-02-12 2009-02-12 Method to predict response to pharmacological chaperone treatment of diseases

Publications (1)

Publication Number Publication Date
CY1121386T1 true CY1121386T1 (el) 2020-05-29

Family

ID=40957500

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20151100595T CY1116466T1 (el) 2008-02-12 2015-07-08 Μεθοδος για την προβλεψη αποκρισης σε φαρμακολογικη θεραπευτικη αγωγη σαπερονης των ασθενειων
CY20191100100T CY1121386T1 (el) 2008-02-12 2019-01-24 Μεθοδος για την προβλεψη αποκρισης των ασθενειων σε φαρμακολογικη θεραπευτικη αγωγη σαπερονης
CY20201101114T CY1123816T1 (el) 2008-02-12 2020-11-25 Μεθοδος για την προβλεψη αποκρισης των ασθενειων σε φαρμακολογικη θεραπευτικη αγωγη σαπερονης

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20151100595T CY1116466T1 (el) 2008-02-12 2015-07-08 Μεθοδος για την προβλεψη αποκρισης σε φαρμακολογικη θεραπευτικη αγωγη σαπερονης των ασθενειων

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20201101114T CY1123816T1 (el) 2008-02-12 2020-11-25 Μεθοδος για την προβλεψη αποκρισης των ασθενειων σε φαρμακολογικη θεραπευτικη αγωγη σαπερονης

Country Status (16)

Country Link
US (7) US8592362B2 (el)
EP (4) EP3824900A1 (el)
JP (6) JP5844045B2 (el)
AU (6) AU2009214648B2 (el)
CA (1) CA2715407C (el)
CY (3) CY1116466T1 (el)
DK (3) DK3470077T3 (el)
ES (3) ES2716502T3 (el)
HR (3) HRP20150728T1 (el)
HU (3) HUE051377T2 (el)
LT (2) LT2946785T (el)
MX (1) MX2010008835A (el)
PL (3) PL2946785T3 (el)
PT (3) PT3470077T (el)
SI (3) SI2252313T1 (el)
WO (1) WO2009102895A2 (el)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2533050T6 (da) 2006-05-16 2015-09-21 Amicus Therapeutics Inc Behandlingsmuligheder ved Fabrys sygdom
HUE051377T2 (hu) 2008-02-12 2021-03-01 Amicus Therapeutics Inc Eljárás betegségek gyógyászati chaperonnal történõ kezelésére adott válasz elõrejelzésére
MX2010009875A (es) * 2008-03-12 2010-11-26 Amicus Therapeutics Inc Ensayos para diagnosticar y evaluar opciones de tratamiento para enfermedad de pompe.
TW201117810A (en) * 2009-10-01 2011-06-01 Baylor Res Inst Treatment of male-pattern baldness by local induction of the metabolic defect of fabry disease
US20120283290A1 (en) * 2011-05-06 2012-11-08 Amicus Therapeutics Inc. Quantitation of gl3 in urine
BR112017005810A2 (pt) 2014-09-30 2018-02-27 Amicus Therapeutics Inc alfa-glucosidase ácida altamente potente com carboidratos melhorados
WO2016149508A1 (en) * 2015-03-19 2016-09-22 Shire Human Genetic Therapies, Inc. Mrna therapy for pompe disease
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
KR102510941B1 (ko) 2015-12-30 2023-03-20 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병 치료용의 강화된 산 알파-글루코시다제
LT3397273T (lt) 2015-12-30 2021-06-25 Amicus Therapeutics, Inc. Patobulinta rūgštinė alfa-gliukozidazė pompe ligos gydymui
EP3432882B1 (en) 2016-03-22 2021-09-01 Amicus Therapeutics, Inc. Methods of treating fabry disease in patients having the g9331a mutation in the gla gene
SG11201808455VA (en) 2016-03-30 2018-10-30 Amicus Therapeutics Inc Formulations comprising recombinant acid alpha-glucosidase
BR112018070189A2 (pt) 2016-03-30 2019-02-19 Amicus Therapeutics, Inc. método para seleção de proteínas recombinantes ricas em m6p
CN109475607B (zh) 2016-03-30 2022-04-26 阿米库斯治疗学公司 包含重组酸性α-葡糖苷酶的配制品
US20190183869A1 (en) 2016-07-19 2019-06-20 Amicus Therapeutics, Inc. Treatment of fabry disease in ert-naïve and ert-experienced patients
JP6546135B2 (ja) 2016-08-24 2019-07-17 株式会社ノリタケカンパニーリミテド 積層造形焼成体、積層造形焼成体の製造方法および積層造形焼成体製造用キット
CA3039673A1 (en) * 2016-10-20 2018-04-26 Sangamo Therapeutics, Inc. Methods and compositions for the treatment of fabry disease
EA202290114A1 (ru) * 2017-03-30 2022-03-29 Амикус Терапьютикс, Инк. Способ отбора рекомбинантных белков с высоким содержанием m6p
DK3624831T3 (da) 2017-05-15 2023-06-26 Amicus Therapeutics Inc Rekombinant human sur alfa-glucosidase
EP4324522A2 (en) 2017-05-30 2024-02-21 Amicus Therapeutics, Inc. Methods of treating fabry patients having renal impairment
KR102631805B1 (ko) 2017-05-30 2024-01-31 아미쿠스 세라퓨틱스, 인코포레이티드 신장 손상을 갖는 파브리 환자를 치료하는 방법
SG11202000423XA (en) 2017-07-19 2020-02-27 Amicus Therapeutics Inc Treatment of fabry disease in ert-naïve and ert-experienced patients
KR20200044908A (ko) 2017-08-28 2020-04-29 아미쿠스 세라퓨틱스, 인코포레이티드 파브리병을 앓는 환자에서 심장 기능을 강화 및/또는 안정화시키는 방법
PL3749308T3 (pl) 2018-02-06 2024-03-25 Amicus Therapeutics, Inc. Leczenie pacjentów z klasyczną chorobą fabry’ego migalastatem
KR20200128676A (ko) 2018-02-06 2020-11-16 아미쿠스 세라퓨틱스, 인코포레이티드 임신 환자의 파브리병 치료를 위한 미갈라스타트의 용도
US20220184185A1 (en) 2018-07-25 2022-06-16 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
US20210315875A1 (en) 2018-08-20 2021-10-14 Amicus Therapeutics, Inc. Methods of Treating Fabry Disease in Patients Having a Mutation in the GLA Gene
NL2021840B1 (en) 2018-10-19 2020-05-13 Univ Leiden Pharmacological Chaperones For Enzyme Treatment Therapy
WO2020046132A1 (en) 2018-08-31 2020-03-05 Leiden University Pharmacological chaperones for enzyme treatment therapy
TW202042812A (zh) 2019-01-22 2020-12-01 美商阿米庫斯醫療股份有限公司 減少法布瑞氏症患者中之腦血管事件之方法
CA3141226A1 (en) 2019-06-11 2020-12-17 Franklin Johnson Methods of treating fabry disease in patients having renal impairment
US11833164B2 (en) * 2019-08-07 2023-12-05 Amicus Therapeutics, Inc. Methods of treating Fabry disease in patients having a mutation in the GLA gene
BR112022004000A2 (pt) 2019-09-06 2022-05-31 Amicus Therapeutics Inc Método para captura e purificação de biológicas
CA3170718A1 (en) * 2020-03-06 2021-09-10 Amicus Therapeutics, Inc. Methods of treating fabry disease in patients having a mutation in the gla gene
US11623916B2 (en) 2020-12-16 2023-04-11 Amicus Therapeutics, Inc. Highly purified batches of pharmaceutical grade migalastat and methods of producing the same
CA3225511A1 (en) 2021-07-12 2023-01-19 Franklin Johnson Methods of treating fabry disease in pediatric patients
WO2023215865A1 (en) 2022-05-05 2023-11-09 Amicus Therapeutics, Inc. Methods for treating pompe disease

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3586908A (en) 1969-02-28 1971-06-22 Robert E Vosteen Automatic potential control system for electrophotography apparatus
US5401650A (en) * 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
US5863903A (en) 1994-03-09 1999-01-26 Novo Nordisk A/S Use of hydroxy alkyl piperidine and pyrrolidine compounds to treat diabetes
US5844102A (en) 1994-07-07 1998-12-01 University Of Maryland Baltimore County Glycohydrolase inhibitors, their preparation and use thereof
EP0959877A4 (en) 1996-04-10 2000-08-23 Univ California CORRECTION OF GENETIC DEFECTS USING CHEMICAL CAPS
US6270954B1 (en) 1996-04-10 2001-08-07 The Regents Of The University Of California Correction of genetic defects using chemical chaperones
US5948653A (en) 1997-03-21 1999-09-07 Pati; Sushma Sequence alterations using homologous recombination
US6274597B1 (en) * 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
US6244113B1 (en) 1999-10-29 2001-06-12 University Of Alabama In Huntsville Method and apparatus for measuring microgravity acceleration
US7842470B2 (en) * 2001-10-09 2010-11-30 Oregon Health & Science University Method for pharmacoperones correction of GnRHR mutant protein misfolding
EP3441090A1 (en) * 2005-05-17 2019-02-13 Amicus Therapeutics, Inc. A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
ES2537089T3 (es) 2005-06-08 2015-06-02 Amicus Therapeutics, Inc. Purificación de imino- y amino-azúcares
EP1888068B1 (en) * 2005-06-08 2014-05-21 Amicus Therapeutics, Inc. Treatment of cns disorders associated with mutations in genes encoding lysosomal enzymes
US7790364B2 (en) * 2006-01-27 2010-09-07 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for high throughput screening of pharmacological chaperones
DK2533050T6 (da) 2006-05-16 2015-09-21 Amicus Therapeutics Inc Behandlingsmuligheder ved Fabrys sygdom
US7501439B2 (en) 2006-05-24 2009-03-10 Amicus Therapeutics, Inc. Tartrate salt of isofagomine and methods of use
EP2150254A4 (en) 2007-04-26 2010-11-10 Amicus Therapeutics Inc DOSAGES FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES WITH PHARMACOLOGICAL CHAPTERONES
US9999618B2 (en) 2007-04-26 2018-06-19 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
HUE051377T2 (hu) 2008-02-12 2021-03-01 Amicus Therapeutics Inc Eljárás betegségek gyógyászati chaperonnal történõ kezelésére adott válasz elõrejelzésére
US20110152319A1 (en) 2008-02-12 2011-06-23 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
US8321148B2 (en) 2008-10-24 2012-11-27 Amicus Therapeutics, Inc. Multiple compartment dosing model
US9206457B2 (en) 2009-05-26 2015-12-08 Amicus Therapeutics, Inc. Utilization of pharmacological chaperones to improve manufacturing and purification of biologics
US20110070643A1 (en) 2009-05-26 2011-03-24 Do Hung V Utilization of Pharmacological Chaperones to Improve Manufacturing and Purification of Biologics
ES2768995T3 (es) 2009-11-17 2020-06-24 Baylor Res Institute 1-desoxigalactonojirimicina para el uso en el tratamiento de una enfermedad cardíaca
SG193379A1 (en) 2011-03-11 2013-10-30 Amicus Therapeutics Inc Dosing regimens for the treatment of fabry disease
US10155027B2 (en) 2012-07-17 2018-12-18 Amicus Therapeutics, Inc. Alpha-galactosidase A and 1-deoxygalactonojirimycin co-formulation for the treatment of fabry disease
US9694056B2 (en) 2012-07-17 2017-07-04 Amicus Therapeutics, Inc. α-galactosidase A and 1-deoxygalactonojirimycin co-formulation
EP3432882B1 (en) 2016-03-22 2021-09-01 Amicus Therapeutics, Inc. Methods of treating fabry disease in patients having the g9331a mutation in the gla gene
US20190183869A1 (en) 2016-07-19 2019-06-20 Amicus Therapeutics, Inc. Treatment of fabry disease in ert-naïve and ert-experienced patients
TW201829770A (zh) 2017-01-10 2018-08-16 美商阿米庫斯醫療股份有限公司 用於治療fabry氏病之重組α-半乳糖苷酶A
KR102631805B1 (ko) 2017-05-30 2024-01-31 아미쿠스 세라퓨틱스, 인코포레이티드 신장 손상을 갖는 파브리 환자를 치료하는 방법
SG11202000423XA (en) 2017-07-19 2020-02-27 Amicus Therapeutics Inc Treatment of fabry disease in ert-naïve and ert-experienced patients
KR20200044908A (ko) 2017-08-28 2020-04-29 아미쿠스 세라퓨틱스, 인코포레이티드 파브리병을 앓는 환자에서 심장 기능을 강화 및/또는 안정화시키는 방법
PL3749308T3 (pl) 2018-02-06 2024-03-25 Amicus Therapeutics, Inc. Leczenie pacjentów z klasyczną chorobą fabry’ego migalastatem
KR20200128676A (ko) 2018-02-06 2020-11-16 아미쿠스 세라퓨틱스, 인코포레이티드 임신 환자의 파브리병 치료를 위한 미갈라스타트의 용도
US20210315875A1 (en) 2018-08-20 2021-10-14 Amicus Therapeutics, Inc. Methods of Treating Fabry Disease in Patients Having a Mutation in the GLA Gene
CA3141226A1 (en) 2019-06-11 2020-12-17 Franklin Johnson Methods of treating fabry disease in patients having renal impairment
US11833164B2 (en) 2019-08-07 2023-12-05 Amicus Therapeutics, Inc. Methods of treating Fabry disease in patients having a mutation in the GLA gene

Also Published As

Publication number Publication date
LT2946785T (lt) 2019-02-11
EP2252313B1 (en) 2015-04-08
US10813921B2 (en) 2020-10-27
EP2252313A4 (en) 2011-04-13
JP2011514152A (ja) 2011-05-06
HUE051377T2 (hu) 2021-03-01
ES2836121T3 (es) 2021-06-24
US20110212996A1 (en) 2011-09-01
US20140206721A1 (en) 2014-07-24
WO2009102895A3 (en) 2009-12-23
AU2014221321A1 (en) 2014-10-02
JP6672013B2 (ja) 2020-03-25
ES2716502T3 (es) 2019-06-12
AU2009214648B2 (en) 2014-11-13
EP3470077A1 (en) 2019-04-17
ES2541933T3 (es) 2015-07-28
DK2252313T3 (en) 2015-07-13
HRP20201827T1 (hr) 2021-01-08
CA2715407A1 (en) 2009-08-20
EP2946785A1 (en) 2015-11-25
HUE026543T2 (hu) 2016-06-28
US9095584B2 (en) 2015-08-04
AU2014221321B2 (en) 2016-05-12
EP2946785B1 (en) 2018-10-24
HRP20190143T1 (hr) 2019-03-22
US20190000818A1 (en) 2019-01-03
US20150342940A1 (en) 2015-12-03
HUE042882T2 (hu) 2019-07-29
EP2252313A2 (en) 2010-11-24
DK2946785T3 (en) 2019-02-18
JP5844045B2 (ja) 2016-01-13
PT2946785T (pt) 2019-02-01
WO2009102895A2 (en) 2009-08-20
SI2252313T1 (sl) 2015-08-31
EP3470077B1 (en) 2020-08-26
JP7277493B2 (ja) 2023-05-19
JP2015091239A (ja) 2015-05-14
US8592362B2 (en) 2013-11-26
PL2252313T3 (pl) 2015-09-30
CY1116466T1 (el) 2017-03-15
AU2016206297A1 (en) 2016-08-04
PT3470077T (pt) 2020-11-30
JP6837469B2 (ja) 2021-03-03
US9545397B2 (en) 2017-01-17
JP2019088289A (ja) 2019-06-13
AU2021218172A1 (en) 2021-10-07
SI2946785T1 (sl) 2019-02-28
PT2252313E (pt) 2015-08-26
SI3470077T1 (sl) 2020-12-31
DK3470077T3 (da) 2020-11-30
USRE48608E1 (en) 2021-06-29
AU2017268649A1 (en) 2018-01-04
LT3470077T (lt) 2021-02-25
JP2016163571A (ja) 2016-09-08
CA2715407C (en) 2022-07-26
AU2009214648A1 (en) 2009-08-20
JP2023109807A (ja) 2023-08-08
JP2021097673A (ja) 2021-07-01
PL2946785T3 (pl) 2019-04-30
AU2019219727A1 (en) 2019-09-12
US20170003301A1 (en) 2017-01-05
MX2010008835A (es) 2010-10-20
HRP20150728T1 (hr) 2015-08-14
AU2019219727B2 (en) 2021-05-20
CY1123816T1 (el) 2022-03-24
EP3824900A1 (en) 2021-05-26
PL3470077T3 (pl) 2021-04-06
US20210251971A1 (en) 2021-08-19

Similar Documents

Publication Publication Date Title
CY1121386T1 (el) Μεθοδος για την προβλεψη αποκρισης των ασθενειων σε φαρμακολογικη θεραπευτικη αγωγη σαπερονης
Perino et al. MTF2 recruits Polycomb Repressive Complex 2 by helical-shape-selective DNA binding
Dangkulwanich et al. Molecular mechanisms of transcription through single-molecule experiments
BR112014027578A2 (pt) método em um sistema de processamento de dados para gerar uma linha de base de uso de energia, sistema de processamento de dados configurado para gerar uma linha de base de uso de energia e meio legível por computador não transitório
Sivaramakrishnan et al. Systematic control of protein interaction using a modular ER/K α-helix linker
Arike et al. Comparison and applications of label-free absolute proteome quantification methods on Escherichia coli
CY1122123T1 (el) Συνθεσεις λιπιδικου νανοσωματιδιου και μεθοδοι για απελευθερωση mrna
Wlodarski et al. Comprehensive structural and substrate specificity classification of the Saccharomyces cerevisiae methyltransferome
AU2013211850A8 (en) Methods for profiling and quantitating cell-free RNA
Aggarwal et al. Single-molecule fluorescence microscopy of native macromolecular complexes
Goldmann Mechanotransduction in cells 1
BR112014030298A8 (pt) Métodos e kits destinados para ensaios baseados em aptâmeros multiplexados
BR112012013362A2 (pt) sistema para a determinação de um valor para pelo menos um parâmetro que descreve a atividade microbiana de organismos biológicos individuais em uma amostra de líquido, e, método para a determinação da atividade microbiana em uma amostra de líquido
BRPI0816393A2 (pt) Método para determinar o número de cópias relativo de uma sequência de polinucleotídeo alvo em um genoma de um indivíduo
DE602008006382D1 (de) Pyridin-boronsäure-quencher zur verwendung in analytsensoren
BR112012028805A2 (pt) composições de endorribonuclease e métodos de uso das mesmas.
BRPI1010693A2 (pt) métodos implementados por computador para marcar e/ou pontuar uma primeira amostra obtida a partir de um sujeito, meios de armazenamento legível em computador de armazenamento de código de programa executável e métodos, sistema e kits de predição de cad em um sujeito
NO20083461L (no) Genekspresjonsmarkorer for kolorektal cancer-prognose
BR112012009481A2 (pt) método e dispositivo para detectar uma pluralidade de alvos em uma amostra biológica, e, kit para detectar uma pluralidade de alvos múltiplos em uma amostra biológica
BRPI0906470A2 (pt) sistema de combinaçao de afinidades e metodo
BR112017020582A2 (pt) composições e métodos para a detecção de um contaminante biológico
CY1119031T1 (el) Βακτηριακως λαμβανομενα, ανεπαφα μινικυτταρα που συμπεριλαμβανουν ρυθμιστικο rna
BRPI0915619A2 (pt) métodos para determinar uma probabilidade de que um sujeito tenha contribuído com material genético para amostra de teste de material genético, para caracterizar amostra de teste de material genético e para determinar se uma pessoa de interesse contribuiu com material genético para uma amostra de teste de material genético, kit para análise de amostra de teste de material genético e sistema para determinar se um sujeito contribuiu com material genético para uma amostra
BR112021022865A2 (pt) Matriz e método para detectar informações espaciais de ácidos nucleicos
BR112015017354A2 (pt) método para detectar pelo menos uma base modificada